167 related articles for article (PubMed ID: 23432943)
1. Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
Cardinal H; Dieudé M; Brassard N; Qi S; Patey N; Soulez M; Beillevaire D; Echeverry F; Daniel C; Durocher Y; Madore F; Hébert MJ
Am J Transplant; 2013 Apr; 13(4):861-874. PubMed ID: 23432943
[TBL] [Abstract][Full Text] [Related]
2. The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection.
Soulez M; Pilon EA; Dieudé M; Cardinal H; Brassard N; Qi S; Wu SJ; Durocher Y; Madore F; Perreault C; Hébert MJ
Circ Res; 2012 Jan; 110(1):94-104. PubMed ID: 22076637
[TBL] [Abstract][Full Text] [Related]
3. Anti-LG3 Antibodies Aggravate Renal Ischemia-Reperfusion Injury and Long-Term Renal Allograft Dysfunction.
Yang B; Dieudé M; Hamelin K; Hénault-Rondeau M; Patey N; Turgeon J; Lan S; Pomerleau L; Quesnel M; Peng J; Tremblay J; Shi Y; Chan JS; Hébert MJ; Cardinal H
Am J Transplant; 2016 Dec; 16(12):3416-3429. PubMed ID: 27172087
[TBL] [Abstract][Full Text] [Related]
4. New insights into immune mechanisms of antiperlecan/LG3 antibody production: Importance of T cells and innate B1 cells.
Padet L; Dieudé M; Karakeussian-Rimbaud A; Yang B; Turgeon J; Cailhier JF; Cardinal H; Hébert MJ
Am J Transplant; 2019 Mar; 19(3):699-712. PubMed ID: 30129231
[TBL] [Abstract][Full Text] [Related]
5. The perlecan fragment LG3 regulates homing of mesenchymal stem cells and neointima formation during vascular rejection.
Pilon EA; Dieudé M; Qi S; Hamelin K; Pomerleau L; Beillevaire D; Durocher Y; Zutter M; Coutu D; Perreault C; Hébert MJ
Am J Transplant; 2015 May; 15(5):1205-18. PubMed ID: 25808553
[TBL] [Abstract][Full Text] [Related]
6. Injury derived autoimmunity: Anti-perlecan/LG3 antibodies in transplantation.
Dieudé M; Cardinal H; Hébert MJ
Hum Immunol; 2019 Aug; 80(8):608-613. PubMed ID: 31029511
[TBL] [Abstract][Full Text] [Related]
7. The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection.
Dieudé M; Bell C; Turgeon J; Beillevaire D; Pomerleau L; Yang B; Hamelin K; Qi S; Pallet N; Béland C; Dhahri W; Cailhier JF; Rousseau M; Duchez AC; Lévesque T; Lau A; Rondeau C; Gingras D; Muruve D; Rivard A; Cardinal H; Perreault C; Desjardins M; Boilard É; Thibault P; Hébert MJ
Sci Transl Med; 2015 Dec; 7(318):318ra200. PubMed ID: 26676607
[TBL] [Abstract][Full Text] [Related]
8. Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat.
Joosten SA; van Dixhoorn MG; Borrias MC; Benediktsson H; van Veelen PA; van Kooten C; Paul LC
Am J Pathol; 2002 Apr; 160(4):1301-10. PubMed ID: 11943715
[TBL] [Abstract][Full Text] [Related]
9. Anti-perlecan antibodies and acute humoral rejection in hypersensitized patients without forbidden HLA specificities after kidney transplantation.
Riesco L; Irure J; Rodrigo E; Guiral S; Ruiz JC; Gómez J; López-Hoyos M; San Segundo D
Transpl Immunol; 2019 Feb; 52():53-56. PubMed ID: 30458294
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic analysis of acute vascular rejection cases after renal transplantation.
Shimizu T; Tanabe T; Omoto K; Ishida H; Tanabe K
Transplant Proc; 2012 Jan; 44(1):230-5. PubMed ID: 22310621
[TBL] [Abstract][Full Text] [Related]
11. Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection.
Sun Q; Liu Z; Chen J; Chen H; Wen J; Cheng D; Li L
Clin J Am Soc Nephrol; 2008 Sep; 3(5):1479-86. PubMed ID: 18579669
[TBL] [Abstract][Full Text] [Related]
12. Human pregnancy and generation of anti-angiotensin receptor and anti-perlecan antibodies.
Hönger G; Cardinal H; Dieudé M; Buser A; Hösli I; Dragun D; Hébert MJ; Schaub S
Transpl Int; 2014 May; 27(5):467-74. PubMed ID: 24661626
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Sera of Recipients with Allograft Rejection Indicates That Keratin 1 Is the Target of Anti-Endothelial Antibodies.
Guo X; Hu J; Luo W; Luo Q; Guo J; Tian F; Ming Y; Zou Y
J Immunol Res; 2017; 2017():8679841. PubMed ID: 28265584
[TBL] [Abstract][Full Text] [Related]
14. Hypothermic Perfusion Modifies the Association Between Anti-LG3 Antibodies and Delayed Graft Function in Kidney Recipients.
Mawad H; Pinard L; Medani S; Chagnon M; Boucquemont J; Turgeon J; Dieudé M; Hamelin K; Rimbaud AK; Belayachi A; Yang B; Collette S; Sénécal L; Foster BJ; Hébert MJ; Cardinal H
Transpl Int; 2023; 36():10749. PubMed ID: 36891519
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial cell apoptosis induced by anti-donor non-MHC antibodies: a possible injury pathway contributing to chronic allograft rejection.
Wu GD; Jin YS; Salazar R; Dai WD; Barteneva N; Barr ML; Barsky LW; Starnes VA; Cramer DV
J Heart Lung Transplant; 2002 Nov; 21(11):1174-87. PubMed ID: 12431491
[TBL] [Abstract][Full Text] [Related]
16. Double Pretransplant Positivity for Autoantibodies to LG3 and Angiotensin II Type 1 Receptor Is Associated With Alloimmune Vascular Injury in Kidney Transplant Recipients.
Carroll R; Turgeon J; Deayton S; Emery T; Bilogrevic F; Jahan S; Rimbaud AK; Georges B; Tavares-Brum A; Hébert MJ; Cardinal H
Transplant Direct; 2023 Feb; 9(2):e1437. PubMed ID: 36743234
[TBL] [Abstract][Full Text] [Related]
17. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice.
Wasowska BA; Qian Z; Cangello DL; Behrens E; Van Tran K; Layton J; Sanfilippo F; Baldwin WM
Transplantation; 2001 Mar; 71(6):727-36. PubMed ID: 11330533
[TBL] [Abstract][Full Text] [Related]
18. Role of Pretransplant Complement-fixing Donor-specific Antibodies Identified by C1q Assay in Kidney Transplantation.
Thammanichanond D; Wiwattanathum P; Mongkolsuk T; Kantachuvesiri S; Worawichawong S; Vallipakorn SA; Kitpoka P
Transplant Proc; 2016 Apr; 48(3):756-60. PubMed ID: 27234729
[TBL] [Abstract][Full Text] [Related]
19. Antibodies beyond HLA.
Nickerson PW; Rush DN
Am J Transplant; 2013 Apr; 13(4):831-832. PubMed ID: 23406413
[No Abstract] [Full Text] [Related]
20. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting.
Wang H; Hosiawa KA; Min W; Yang J; Zhang X; Garcia B; Ichim TE; Zhou D; Lian D; Kelvin DJ; Zhong R
J Immunol; 2003 Oct; 171(7):3823-36. PubMed ID: 14500684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
